Research Article
Switching from Intravitreal Ranibizumab to Bevacizumab for
Age-Related Macular Degeneration
Table 1
Demographics and characteristics of patients.
| | Pt | Age | Sex | Duration of IVR treatment (months) | Number of IVR | Prior PDT | Duration of IVB treatment (months) | Number of IVB |
| | 1 | 79 | Female | 6 | 3 | (+) | 13 | 3 | | 2 | 79 | Female | 7 | 3 | (−) | 12 | 1 | | 3 | 66 | Female | 11 | 5 | (−) | 11 | 3 | | 4 | 62 | Male | 8 | 5 | (+) | 9 | 3 | | 5 | 76 | Female | 10 | 6 | (−) | 10 | 6 | | 6 | 65 | Female | 10 | 6 | (−) | 10 | 4 | | 7 | 68 | Male | 8 | 6 | (−) | 11 | 6 |
|
|
IVR: intravitreal ranibizumab; PDT: photodynamic therapy; IVB: intravitreal bevacizumab.
|
